The document is a financial analysis by Deutsche Bank on Shire, highlighting its potential for growth despite challenges in haemophilia. It discusses the company's long-term targets, synergies, and deleveraging strategies. The analysis includes a table of scenario-based share price values and emphasizes Shire's undervaluation compared to EU Pharma.
doj/DataSet10/EFTA01385517.pdf
{"title":"Deutsche Bank Research European Equity Focus","key_people":["Richard Parkes"],"document_date":"January 2018","document_type":"tabular","document_subtype":"financial analysis","key_organizations":["Deutsche Bank","Shire"],"reference_numbers":["DB-SDNY-0086803","SDNY_GM_00232987","EFTA01385517"]}